SCHEMBL10102646

SCHEMBL10102646

N#Cc1cccc(-c2nc3ccc(C(F)(F)F)cc3cc2CCCO)c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSK P43235 4/20 0.47
KCNH2 Q12809 3/20 0.47
TRPA1 O75762 1/20 0.41
PTPN5 P54829 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.38
NAMPT P43490 1/20 0.37
DGAT1 O75907 1/20 0.36
SOAT1 P35610 1/20 0.36
ADORA2A P29274 3/20 0.36
MAT2A P31153 1/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2B Q13224 1/20 0.36
ADORA1 P30542 3/20 0.36
CTSS P25774 2/20 0.36
ADORA2B P29275 1/20 0.35
MRGPRX4 Q96LA9 1/20 0.35
CFTR P13569 1/20 0.35
RORC P51449 1/20 0.35
S1PR1 P21453 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10102645 0.90 CNR2 (0.38) CTSKKCNH2TRPA1PTPN5NAMPT
SCHEMBL3383001 0.84 DHODH (0.45) CTSKKCNH2DGAT1
SCHEMBL10102653 0.84 CTSK (0.40) CTSKKCNH2NAMPT
SCHEMBL10102630 0.80 KMT2A (0.38) PTGDR2ADORA2AADORA1ADORA2BCFTR
SCHEMBL10102652 0.79 TRPA1 (0.43) CTSKKCNH2TRPA1NAMPT
SCHEMBL13005263 0.79 DHFR (0.40) CTSKKCNH2NAMPT
SCHEMBL10107977 0.78 NPBWR1 (0.43) CTSKKCNH2
SCHEMBL13005264 0.78 KDM4E (0.39) CTSKKCNH2TRPA1NAMPTDGAT1
SCHEMBL10102671 0.77 DHODH (0.46) KCNH2DGAT1
SCHEMBL10102644 0.76 GPBAR1 (0.42) CTSKKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207345-B2 Antitumor agents; use in combination with other drugs such as pentamidine MERCK PATENT GMBH (DE) 2012-06-26 US disclosed
US-8207345-B2 Antitumor agents; use in combination with other drugs such as pentamidine MERCK PATENT GMBH (DE) 2012-06-26 US disclosed
EP-1891011-B1 TETRAHYDROQUINOLINES USED IN THE FORM OF MODULATORS OF MITOTIC MOTOR-PROTEINS EG5 MERCK PATENT GMBH (DE) 2010-12-08 EP disclosed
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 MERCK PATENT GMBH (DE) 2008-08-21 US disclosed
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 MERCK PATENT GMBH (DE) 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 KIF5A, KIF5C, KIF5B CTSK 3797/4885KCNH2 1709/4885TRPA1 4742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.